Interplay of UDP-Glucuronosyltransferase and CYP2C8 for CYP2C8 Mediated Drug Oxidation and Its Impact on Drug–Drug Interaction Produced by Standardized CYP2C8 Inhibitors, Clopidogrel and Gemfibrozil

Inhibition of CYP2C8 by Acyl Glucuronides of Gemfibrozil and Clopidogrel: Pharmacological Significance, Progress and Challenges

(2022) Manish B. Shah   Biomolecules

Clopidogrel and Gemfibrozil Strongly Inhibit the CYP2C8-dependent Formation of 3-Hydroxydesloratadine and Increase Desloratadine Exposure In Humans

(2019) Matti K Itkonen et al.   DRUG METABOLISM AND DISPOSITION

Quantitative Analysis of Complex Drug-Drug Interactions between Cerivastatin and Metabolism/Transport Inhibitors Using Physiologically Based Pharmacokinetic Modeling

(2018) Yoshiaki Yao et al.   DRUG METABOLISM AND DISPOSITION

Glucuronides as Potential Anionic Substrates of Human Cytochrome P450 2C8 (CYP2C8)

(2017) Yong Ma et al.   JOURNAL OF MEDICINAL CHEMISTRY

Simulations of Cytochrome P450 3A4-Mediated Drug-Drug Interactions by Simple Two-Compartment Model-Assisted Static Method

(2017) Katsumi Iga et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Quantitative Analysis of Complex Drug–Drug Interactions Between Repaglinide and Cyclosporin A/Gemfibrozil Using Physiologically Based Pharmacokinetic Models With In Vitro Transporter/Enzyme Inhibition Data

(2017) Soo-Jin Kim et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Revisiting the Latency of Uridine Diphosphate-Glucuronosyltransferases (UGTs)—How Does the Endoplasmic Reticulum Membrane Influence Their Function?

(2017) et al.   Pharmaceutics

Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters

(2016) Aleksi Tornio et al.   Expert Opinion on Drug Metabolism & Toxicology

Dynamic and Static Simulations of Fluvoxamine-Perpetrated Drug-Drug Interactions Using Multiple Cytochrome P450 Inhibition Modeling, and Determination of Perpetrator-Specific CYP Isoform Inhibition Constants and Fractional CYP Isoform Contributions to Victim Clearance

(2016) Katsumi Iga   JOURNAL OF PHARMACEUTICAL SCIENCES

Structure and Protein–Protein Interactions of Human UDP-Glucuronosyltransferases

(2016) Ryoichi Fujiwara et al.   Frontiers in Pharmacology

Underlying mechanism of drug–drug interaction between pioglitazone and gemfibrozil: Gemfibrozil acyl-glucuronide is a mechanism-based inhibitor of CYP2C8

(2015) Motoi Takagi et al.   Drug Metabolism and Pharmacokinetics

Simulation of Metabolic Drug-Drug Interactions Perpetrated by Fluvoxamine Using Hybridized Two-Compartment Hepatic Drug-Pool-Based Tube Modeling and Estimation of In Vivo Inhibition Constants

(2015) Katsumi Iga   JOURNAL OF PHARMACEUTICAL SCIENCES

Use of Three-Compartment Physiologically Based Pharmacokinetic Modeling to Predict Hepatic Blood Levels of Fluvoxamine Relevant for Drug-Drug Interactions

(2015) Katsumi Iga   JOURNAL OF PHARMACEUTICAL SCIENCES

Statin Lactonization by Uridine 5′-Diphospho-glucuronosyltransferases (UGTs)

(2015) Tom J. J. Schirris et al.   MOLECULAR PHARMACEUTICS

Glucuronidation Converts Clopidogrel to a Strong Time-Dependent Inhibitor of CYP2C8: A Phase II Metabolite as a Perpetrator of Drug–Drug Interactions

(2014) A Tornio et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Mechanistic Modeling to Predict the Transporter- and Enzyme-Mediated Drug-Drug Interactions of Repaglinide

(2013) Manthena V. S. Varma et al.   PHARMACEUTICAL RESEARCH

The effect of genetic polymorphisms in UGT2B15 on the pharmacokinetic profile of sipoglitazar, a novel anti-diabetic agent

(2012) Frances Stringer et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast

(2011) Tiina Karonen et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Mechanism-Based Inactivation of CYP2C8 by Gemfibrozil Occurs Rapidly in Humans

(2011) J Honkalammi et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Evaluation of CYP2C8 Inhibition In Vitro: Utility of Montelukast as a Selective CYP2C8 Probe Substrate

(2011) B. M. VandenBrink et al.   DRUG METABOLISM AND DISPOSITION

Metabolic Fate of Sipoglitazar a Novel Oral PPAR Agonist with Activities for PPAR-γ, -α and -δ, in Rats and Monkeys and Comparison with Humans In Vitro

(2011) Mitsuhiro Nishihara et al.   Drug Metabolism and Pharmacokinetics

Repaglinide-gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanism

(2010) Jinping Gan et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

CYP2C8 Exists as a Dimer in Natural Membranes

(2010) G. Hu et al.   DRUG METABOLISM AND DISPOSITION

Identification of Novel Metabolic Pathways of Pioglitazone in Hepatocytes: N-Glucuronidation of Thiazolidinedione Ring and Sequential Ring-Opening Pathway

(2010) M. Uchiyama et al.   DRUG METABOLISM AND DISPOSITION

System-Dependent Outcomes during the Evaluation of Drug Candidates as Inhibitors of Cytochrome P450 (CYP) and Uridine Diphosphate Glucuronosyltransferase (UGT) Enzymes: Human Hepatocytes versus Liver Microsomes versus Recombinant Enzymes

(2010) Andrew Parkinson et al.   Drug Metabolism and Pharmacokinetics

CYP2C8 Activity Recovers within 96 Hours after Gemfibrozil Dosing: Estimation of CYP2C8 Half-Life Using Repaglinide as an in Vivo Probe

(2009) J. T. Backman et al.   DRUG METABOLISM AND DISPOSITION